Full description
The dataset used for this study contained the estimated pharmacokinetic (PK) data after intravenous tobramycin administration to children and adults with and without cystic fibrosis, which was previously analysed using a mixed effects modelling approach [1]. Hence, the following two compartment PK parameters: individual clearance (CL), central volume of distribution (V1), distributional clearance (Q) and peripheral volume of distribution (V2) estimates for each patient were available. For the purpose of this study, these individual PK parameter estimates were considered as data. From the whole dataset [1], only patients aged 1-25 years were included which resulted in data from 570 subjects (6.4 to 120 kg, 204 male patients) treated with tobramycin. Included in the Balanced prior data set are: ID (subejct identifier), AGE (age in years), WT (total body weight in kg), CL (clearance of tobramycin from the central compartment), V1 (volume of distribution of the central compartment), Q (intercompartmental clearance), and V2 (volume of distribution of the peripheral compartment).Issued: 2018
Data time period: 2013
User Contributed Tags
Login to tag this record with meaningful keywords to make it easier to discover
Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis
local : UQ:282744
Hennig, Stefanie, Standing, Joseph F., Staatz, Christine E. and Thomson, Alison H. (2013). Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. Clinical Pharmacokinetics, 52 (4), 289-301. doi: 10.1007/s40262-013-0036-y
Using a Bayesian modelling approach with balanced informative prior to develop an optimal paediatric dosing paradigm using scarce PK data
local : UQ:290809
Klein, Kerenaftal, Hennig, Stefanie and Paul, Sanjoy Ketan (2013). Using a Bayesian modelling approach with balanced informative prior to develop an optimal paediatric dosing paradigm using scarce PK data. 15th Annual Population Approach Group Australia and New Zealand Meeting (PAGANZ 2013), Brisbane, Australia, 13-15 February 2013.
A Bayesian modelling approach with balancing informative prior for analysing imbalanced data
local : UQ:384751
Klein, Kerenaftali, Hennig, Stefanie and Paul, Sanjoy Ketan (2016). A Bayesian modelling approach with balancing informative prior for analysing imbalanced data. PLoS One, 11 (4) e0152700, e0152700.1-e0152700.12. doi: 10.1371/journal.pone.0152700
Bayesian estimation of tobramycin exposure in cystic fibrosis
local : UQ:410202
Barras, Michael A., Serisier, David, Hennig, Stefanie, Jess, Katrina and Norris, Ross L. G. (2016). Bayesian estimation of tobramycin exposure in cystic fibrosis. Antimicrobial Agents and Chemotherapy, 60 (11), 6698-6702. doi: 10.1128/AAC.01131-16
Usage and monitoring of intravenous tobramycin in cystic fibrosis in Australia and the United Kingdom
local : UQ:371631
Paviour, Sophie, Hennig, Stefanie and Staatz, Christine E. (2016). Usage and monitoring of intravenous tobramycin in cystic fibrosis in Australia and the United Kingdom. Journal of Pharmacy Practice and Research, 46 (1), 15-21. doi: 10.1002/jppr.1145
A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis.
local : UQ:383124
Noor Harun, Sabariah, Wainwright, Claire, Klein, Kerenaftali and Hennig, Stefanie (2016). A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis.. Paediatric Respiratory Reviews, 20, 55-66. doi: 10.1016/j.prrv.2016.03.002
Research Data Collections
local : UQ:289097
School of Pharmacy Publications
local : UQ:3833
- DOI : 10.14264/UQL.2016.141
